Need Help?

The Precision Medicine in Liver Cancer across an Asia-pacific NETwork (PLANET)

Hepatocellular carcinoma (HCC) is the 2nd most important cause of cancer deaths in the world. The outcomes of treatment in HCC are poor compared to other common cancers because there are no good systemic therapy drugs. We designed a prospective study that will involve 5 different sites within the established Asia-Pacific Hepatocellular Carcinoma Trials Group to study both the genetics as well as immune profiles of HCC in different ethnicities. In this study, patients will be followed-up and at recurrence the tissues to understand the evolution of disease progression. Here, we presented both the genomic (DNA) and phenotypic (RNA) evolution for the first batch of 56 patients. The detailed findings will be listed in the corresponding publication soon.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001006570 HiSeq X Ten Illumina HiSeq 4000 70
EGAD00001008647 HiSeq X Ten Illumina HiSeq 4000 -
EGAD00001008648 Illumina HiSeq 4000 -
EGAD00001009041 -
EGAD00001009042 18
EGAD00001009858 HiSeq X Ten Illumina HiSeq 4000 12
EGAD00001009859 Illumina HiSeq 4000 -
Publications Citations
Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study.
Natl Sci Rev 9: 2022 nwab192
Pan-cancer pervasive upregulation of 3' UTR splicing drives tumourigenesis.
Nat Cell Biol 24: 2022 928-939
Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma.
BMC Cancer 23: 2023 118
A genomic enhancer signature associates with hepatocellular carcinoma prognosis.
JHEP Rep 5: 2023 100715